Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies

Next Previous
X
Search
Trial Profile

Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bexicaserin (Primary)
  • Indications Developmental disabilities; Dravet syndrome; Early infantile epileptic encephalopathy 2; Lennox-Gastaut syndrome; Tuberous sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PACIFIC
  • Sponsors Longboard Pharmaceuticals

    • Most Recent Events

    • 05 Dec 2024 According to Longboard Pharmaceuticals media release, analysis of the Phase 1b/2a PACIFIC Study will be presented on Monday, December 9, 2024, 12:00 -1:45pm PT, at the American Epilepsy Society (AES) Annual Meeting in Los Angeles, U.S.
    • 05 Dec 2024 According to Longboard Pharmaceuticals media release, "Preliminary Results from a Controlled Study of Sleep Disruption in Caregivers of Individuals with Lennox-Gastaut Syndrome" will be presented on Saturday, December 7, 2024, 12:00 - 2:00pm PT, at the American Epilepsy Society (AES) Annual Meeting in Los Angeles, U.S.
    • 05 Dec 2024 According to Longboard Pharmaceuticals media release, additional efficacy analyses from this study and the Interim Results of a Phase 1b/2a PACIFIC Study Open-Label Extension (OLE), will be presented on Saturday, December 7, 2024, 12:00 - 2:00pm PT, at the American Epilepsy Society (AES) Annual Meeting in Los Angeles, U.S.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top